By Sheri Kasprzak
New York, Oct. 19 - Innogenetics NV said it completed a private placement of stock for €8 million.
The company issued 827,300 shares at €9.67 each to Global Opportunities Fund.
The investment brings Global Opportunities' ownership of Innogenetics to 6.3%. The investor had previously held 3.7% of the issuer's stock.
Based in Gent, Belgium, Innogenetics is a biopharmaceutical company focused on diagnostics and therapeutic vaccines.
| Issuer: | Innogenetics NV
|
| Issue: | Stock
|
| Amount: | €8 million
|
| Shares: | 827,300
|
| Price: | €9.67
|
| Warrants: | No
|
| Investor: | Global Opportunities Fund
|
| Settlement date: | Oct. 19
|
| Stock price: | €9.60 at close Oct. 19
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
